- Home
- Automated
- NDF A-Z listing
- Recombinant Factor VIII [Afstyla]
R
Recombinant Factor VIII [Afstyla]
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredients: Coagulation Factor VIII (Recombinant) | Recombinant Factor VIII
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
19/12/2022 Recombinant blood products for prophylaxis and management of haemophilia A and B>
[R] The Ministry of Health’s Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:
Octocog alfa (Advate) 250 international units, 500 international units, 1000 international units and 1500 international units powder and solvent for solution for injection
Rurioctocog alfa pegol (Adynovate) 250 international units, 500 international units, 1000 international units, 1500 international units, 2000 international units and 3000 international units powder and solvent for solution for injection
Nonacog alfa (BeneFIX) 250 international units, 500 international units, 1000 international units and 2000 international units powder and solvent for solution for injection
[NR] Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.
The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIAL [SIN15823P]
AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL [SIN15824P]
AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL [SIN15821P]
AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL [SIN15820P]
AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIAL [SIN15822P]